Mechanism of Action

Targeted to identify

Tight binding

Clears injection site rapidly

Identifies lymph nodes

References: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2019. 2. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680-8. 3. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol. 2013; doi 10.1245/s10434-013-2887-8. 4. Vera, DR, Tokin CA. Tilmanocept: a synthetic receptor-targeted molecule for sentinel lymph node mapping. International Atomic Energy Agency (IAEA) Publication 2014; Chapter X: In Press.